Results 141 to 150 of about 175,758 (265)

Tjalma Syndrome-A Rare but Real Manifestation of Systemic Lupus Erythematosus. [PDF]

Clin Case Rep
Khan Z, Asad A, Ullah W, Muhammadi L.
europepmc   +1 more source

Type I interferon drives dysfunction of a distinct CD8+ HLA‐DRB1+ T cell subset in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long, Elio Carmona, Mikhail G Dozmorov, Amr H Sawalha   +3 more
wiley   +1 more source

Chronic heat-induced discoid lupus erythematosus. [PDF]

JAAD Case Rep
Araghi S, Pham CT, Ederaine S, Linden K.
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study. [PDF]

Lupus Sci Med
Gasparotto M, Mattioli I, Alti E, Biancalana E, Canfora M, Chiara E, Di Maso V, Duro G, Ferraro A, Lisi M, Malandrino D, Palmerini M, Urban ML, Vrola L, Silvestri E, Bettiol A, Emmi G.   +16 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Polypharmacy in Adults With Systemic Lupus Erythematosus. [PDF]

Arthritis Care Res (Hoboken)
Yang J, Growdon ME, Fitzpatrick J, Dunlop-Thomas C, Hoge C, Covinsky KE, Bowling CB, Lim SS, Yazdany J, Plantinga LC.   +9 more
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

A Case of Systemic Lupus Erythematosus Involving the Larynx. [PDF]

Cureus
Shaikh AF, Harkare V, Dhoke PR, Idrees FI, Dhoke AR.   +4 more
europepmc   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source